Drug Trial Radar · NCT00398931
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,099
Actual
Start
Feb 1998
Primary completion
Oct 2003
Study completion Oct 2003
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 60 years, up to 86 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly assigned to receive alendronate (either 5 or 10 mg/day) or matching placebo during the next 5 years, in order to evaluate the effects of continuing or discontinuing alendronate treatment on bone mineral density and biochemical markers of bone turnover.
Conditions
- Osteoporosis, Postmenopausal
Interventions
MK0217, alendronate sodium / Duration of Treatment : 5 YearsDrug
Comparator : placebo (unspecified) /Duration of Treatment : 5 YearsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total hip bone mineral density (BMD)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.